This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ueki, K. Articles by Louis, D. N. Search for Related Content PubMed PubMed Citation Articles by Ueki, K. Articles by Louis, D. N.

CDKN2/p16 or RB Alterations Occur in the Majority of Glioblastomas and Are Inversely Correlated¹

Molecular Neuro-Oncology Laboratory, Neurosurgical and Neurology Services and Departments of Pathology [K. U., Y. O., J. W. H., D. N. L.] and Radiation Oncology [J. T. E.], Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, and Institute of Neuropathology, University Hospital, Bonn, Germany [A. v. D.]

p16 is involved in a cell cycle regulatory cascade that includes cyclin-dependent kinase 4 (cdk4), cyclin D1, and pRb (retinoblastoma). Alterations of each of these components have been described in primary human glioblastoma multiforme (GBM) or in GBM cell lines. Because perturbation of any component in this pathway may have similar oncogenic effects, we studied the relationship between abnormalities of CDKN2/p16 and RB, the two commonly involved tumor suppressor genes, in 55 astrocytic gliomas (42 GBMs, 8 anaplastic astrocytomas, and 5 astrocytomas). By using comparative multiplex PCR, homozygous deletions of the CDKN2/p16 gene were detected in 24 GBMs (57%) and in 2 anaplastic astrocytomas. Two additional GBMs and one anaplastic astrocytoma had allelic loss of chromosome 9p, as assessed by microsatellite polymorphisms flanking the CDKN2/p16 region. Single-strand conformation polymorphism and DNA sequencing analysis of all three coding exons of CDKN2/p16 revealed a frameshift mutation (four-bp deletion) in one of the three GBMs that had lost the remaining 9p allele. Allelic loss of chromosome 13q at the RB gene, RB gene mutations, or loss of pRb expression was noted in 14 GBMs (33%) and 2 anaplastic astrocytomas. Thirty-six of 42 GBMs (86%) had alterations of either CDKN2/p16 (n = 22), RB (n = 10), or both (n = 4); these two genetic changes, however, were relatively exclusive (P = 0.003). Furthermore, of the six GBMs without either CDKN2/p16 or RB gene abnormalities, one case had CDK4 gene amplification. These data indicate that the vast majority of GBMs probably have inactivation of the p16-cdk4/cyclin D1-pRb pathway. The findings also provide corroborative evidence that CDKN2/p16 and RB are the critical glioma tumor suppressor genes on chromosomes 9p and 13q, respectively.

¹ This study was supported by NIH Grant CA 57683.

² To whom requests for reprints should be addressed, at Molecular Neuro-Oncology Laboratory, CNY6, Massachusetts General Hospital-East, 149 13th Street, Charlestown, MA 02129. Phone: (617) 726-5510; Fax: (617) 726-5079.

Received 8/10/95. Accepted 10/31/95.

This article has been cited by other articles:

				P. Y. Wen and S. Kesari Malignant Gliomas in Adults N. Engl. J. Med., July 31, 2008; 359(5): 492 - 507. [Full Text] [PDF]

				F. B. Furnari, T. Fenton, R. M. Bachoo, A. Mukasa, J. M. Stommel, A. Stegh, W. C. Hahn, K. L. Ligon, D. N. Louis, C. Brennan, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment Genes & Dev., November 1, 2007; 21(21): 2683 - 2710. [Abstract] [Full Text] [PDF]

				H. Jiang, C. Gomez-Manzano, H. Aoki, M. M. Alonso, S. Kondo, F. McCormick, J. Xu, Y. Kondo, B. N. Bekele, H. Colman, et al. Examination of the Therapeutic Potential of Delta-24-RGD in Brain Tumor Stem Cells: Role of Autophagic Cell Death J Natl Cancer Inst, September 19, 2007; 99(18): 1410 - 1414. [Abstract] [Full Text] [PDF]

				M. M. Alonso, M. Cascallo, C. Gomez-Manzano, H. Jiang, B. N. Bekele, A. Perez-Gimenez, F. F. Lang, Y. Piao, R. Alemany, and J. Fueyo ICOVIR-5 Shows E2F1 Addiction and Potent Antiglioma Effect In vivo Cancer Res., September 1, 2007; 67(17): 8255 - 8263. [Abstract] [Full Text] [PDF]

				S. M. Dunlap, J. Celestino, H. Wang, R. Jiang, E. C. Holland, G. N. Fuller, and W. Zhang Insulin-like growth factor binding protein 2 promotes glioma development and progression PNAS, July 10, 2007; 104(28): 11736 - 11741. [Abstract] [Full Text] [PDF]

				A. Pandita, A. Balasubramaniam, R. Perrin, P. Shannon, and A. Guha Malignant and benign ganglioglioma: A pathological and molecular study Neuro-oncol, April 1, 2007; 9(2): 124 - 134. [Abstract] [Full Text] [PDF]

				D. A. Reardon, J. N. Rich, H. S. Friedman, and D. D. Bigner Recent Advances in the Treatment of Malignant Astrocytoma J. Clin. Oncol., March 10, 2006; 24(8): 1253 - 1265. [Abstract] [Full Text] [PDF]

				C. Gomez-Manzano, W.K. A. Yung, R. Alemany, and J. Fueyo Genetically modified adenoviruses against gliomas: From bench to bedside Neurology, August 10, 2004; 63(3): 418 - 426. [Abstract] [Full Text] [PDF]

				C. Yang, V. Ionescu-Tiba, K. Burns, M. Gadd, L. Zukerberg, D. N. Louis, D. Sgroi, and E. V. Schmidt The Role of the Cyclin D1-Dependent Kinases in ErbB2-Mediated Breast Cancer Am. J. Pathol., March 1, 2004; 164(3): 1031 - 1038. [Abstract] [Full Text] [PDF]

				T. T. Batchelor, R. A. Betensky, J. M. Esposito, L.-D. D. Pham, M. V. Dorfman, N. Piscatelli, S. Jhung, D. Rhee, and D. N. Louis Age-Dependent Prognostic Effects of Genetic Alterations in Glioblastoma Clin. Cancer Res., January 1, 2004; 10(1): 228 - 233. [Abstract] [Full Text] [PDF]

				L. M. Backlund, B. R. Nilsson, H. M. Goike, E. E. Schmidt, L. Liu, K. Ichimura, and V. P. Collins Short Postoperative Survival for Glioblastoma Patients with a Dysfunctional Rb1 Pathway in Combination with No Wild-type PTEN Clin. Cancer Res., September 15, 2003; 9(11): 4151 - 4158. [Abstract] [Full Text] [PDF]

				T. Tsutsui, S.-i. Kumakura, A. Yamamoto, H. Kanai, Y. Tamura, T. Kato, M. Anpo, H. Tahara, and J.C. Barrett Association of p16INK4a and pRb inactivation with immortalization of human cells Carcinogenesis, December 1, 2002; 23(12): 2111 - 2117. [Abstract] [Full Text] [PDF]

				F. F. Lang, M. R. Gilbert, V. K. Puduvalli, J. Weinberg, V. A. Levin, W.K. A. Yung, R. Sawaya, G. N. Fuller, and C. A. Conrad Toward better early-phase brain tumor clinical trials: A reappraisal of current methods and proposals for future strategies Neuro-oncol, October 1, 2002; 4(4): 268 - 277. [Abstract] [PDF]

				M. Mirjany, L. Ho, and G. M. Pasinetti Role of Cyclooxygenase-2 in Neuronal Cell Cycle Activity and Glutamate-Mediated Excitotoxicity J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 494 - 500. [Abstract] [Full Text] [PDF]

				T. Plath, M. Peters, K. Detjen, M. Welzel, Z. von Marschall, C. Radke, B. Wiedenmann, and S. Rosewicz Overexpression of pRB in Human Pancreatic Carcinoma Cells: Function in Chemotherapy-Induced Apoptosis J Natl Cancer Inst, January 16, 2002; 94(2): 129 - 142. [Abstract] [Full Text] [PDF]

				K. Ueki, R. Nishikawa, Y. Nakazato, T. Hirose, J. Hirato, N. Funada, T. Fujimaki, S. Hojo, O. Kubo, T. Ide, et al. Correlation of Histology and Molecular Genetic Analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 Astrocytic and Oligodendroglial Tumors Clin. Cancer Res., January 1, 2002; 8(1): 196 - 201. [Abstract] [Full Text] [PDF]

				S. Kunwar, G. Mohapatra, A. Bollen, K. R. Lamborn, M. Prados, and B. G. Feuerstein Genetic Subgroups of Anaplastic Astrocytomas Correlate with Patient Age and Survival Cancer Res., October 1, 2001; 61(20): 7683 - 7688. [Abstract] [Full Text] [PDF]

				A. Chakravarti, M. A. Delaney, E. Noll, P. McL. Black, J. S. Loeffler, A. Muzikansky, and N. J. Dyson Prognostic and Pathologic Significance of Quantitative Protein Expression Profiling in Human Gliomas Clin. Cancer Res., August 1, 2001; 7(8): 2387 - 2395. [Abstract] [Full Text] [PDF]

				J. Katchanov, C. Harms, K. Gertz, L. Hauck, C. Waeber, L. Hirt, J. Priller, R. von Harsdorf, W. Bruck, H. Hortnagl, et al. Mild Cerebral Ischemia Induces Loss of Cyclin-Dependent Kinase Inhibitors and Activation of Cell Cycle Machinery before Delayed Neuronal Cell Death J. Neurosci., July 15, 2001; 21(14): 5045 - 5053. [Abstract] [Full Text] [PDF]

				E. A. Maher, F. B. Furnari, R. M. Bachoo, D. H. Rowitch, D. N. Louis, W. K. Cavenee, and R. A. DePinho Malignant glioma: genetics and biology of a grave matter Genes & Dev., June 1, 2001; 15(11): 1311 - 1333. [Full Text] [PDF]

				Y. Ino, R. A. Betensky, M. C. Zlatescu, H. Sasaki, D. R. Macdonald, A. O. Stemmer-Rachamimov, D. A. Ramsay, J. G. Cairncross, and D. N. Louis Molecular Subtypes of Anaplastic Oligodendroglioma: Implications for Patient Management at Diagnosis Clin. Cancer Res., April 1, 2001; 7(4): 839 - 845. [Abstract] [Full Text]

				X. Chen, M. Lowe, T. Herliczek, M. J. Hall, C. Danes, D. A. Lawrence, and K. Keyomarsi Protection of Normal Proliferating Cells Against Chemotherapy by Staurosporine-Mediated, Selective, and Reversible G1 Arrest J Natl Cancer Inst, December 20, 2000; 92(24): 1999 - 2008. [Abstract] [Full Text] [PDF]

				C. Abate-Shen and M. M. Shen Molecular genetics of prostate cancer Genes & Dev., October 1, 2000; 14(19): 2410 - 2434. [Full Text]

				T. Kilic, J. A. Alberta, P. R. Zdunek, M. Acar, P. Iannarelli, T. O’Reilly, E. Buchdunger, P. M. Black, and C. D. Stiles Intracranial Inhibition of Platelet-derived Growth Factor-mediated Glioblastoma Cell Growth by an Orally Active Kinase Inhibitor of the 2-Phenylaminopyrimidine Class Cancer Res., September 1, 2000; 60(18): 5143 - 5150. [Abstract] [Full Text]

				R. M. Reis, D. Konu-Lebleblicioglu, J. M. Lopes, P. Kleihues, and H. Ohgaki Genetic Profile of Gliosarcomas Am. J. Pathol., February 1, 2000; 156(2): 425 - 432. [Abstract] [Full Text] [PDF]

				P. Kleihues and H. Ohgaki Phenotype vs Genotype in the Evolution of Astrocytic Brain Tumors Toxicol Pathol, January 1, 2000; 28(1): 164 - 170. [Abstract] [PDF]

				K. Ichimura, M. B. Bolin, H. M. Goike, E. E. Schmidt, A. Moshref, and V. P. Collins Deregulation of the p14ARF/MDM2/p53 Pathway Is a Prerequisite for Human Astrocytic Gliomas with G1-S Transition Control Gene Abnormalities Cancer Res., January 1, 2000; 60(2): 417 - 424. [Abstract] [Full Text]

				M. J. Riemenschneider, R. Buschges, M. Wolter, J. Reifenberger, J. Bostrom, J. A. Kraus, U. Schlegel, and G. Reifenberger Amplification and Overexpression of the MDM4 (MDMX) Gene from 1q32 in a Subset of Malignant Gliomas without TP53 Mutation or MDM2 Amplification Cancer Res., December 1, 1999; 59(24): 6091 - 6096. [Abstract] [Full Text] [PDF]

				G. P. Nielsen, A. O. Stemmer-Rachamimov, Y. Ino, M. B. Moller, A. E. Rosenberg, and D. N. Louis Malignant Transformation of Neurofibromas in Neurofibromatosis 1 Is Associated with CDKN2A/p16 Inactivation Am. J. Pathol., December 1, 1999; 155(6): 1879 - 1884. [Abstract] [Full Text] [PDF]

				C. Raffel, L. Frederick, J. R. O'Fallon, P. Atherton-Skaff, A. Perry, R. B. Jenkins, and C. D. James Analysis of Oncogene and Tumor Suppressor Gene Alterations in Pediatric Malignant Astrocytomas Reveals Reduced Survival for Patients with PTEN Mutations Clin. Cancer Res., December 1, 1999; 5(12): 4085 - 4090. [Abstract] [Full Text] [PDF]

				A. Kubo, K. Nakagawa, R. K. Varma, N. K. Conrad, J. Q. Cheng, W.-C. Lee, J. R. Testa, B. E. Johnson, F. J. Kaye, and M. J. Kelley The p16 Status of Tumor Cell Lines Identifies Small Molecule Inhibitors Specific for Cyclin-dependent Kinase 4 Clin. Cancer Res., December 1, 1999; 5(12): 4279 - 4286. [Abstract] [Full Text] [PDF]

				R. Y. Chung, Y. Saeki, and E. A. Chiocca B-myb Promoter Retargeting of Herpes Simplex Virus gamma 34.5 Gene-Mediated Virulence toward Tumor and Cycling Cells J. Virol., September 1, 1999; 73(9): 7556 - 7564. [Abstract] [Full Text]

				H. Harada, K. Nakagawa, S. Iwata, M. Saito, Y. Kumon, S. Sakaki, K. Sato, and K. Hamada Restoration of Wild-Type p16 Down-Regulates Vascular Endothelial Growth Factor Expression and Inhibits Angiogenesis in Human Gliomas Cancer Res., August 1, 1999; 59(15): 3783 - 3789. [Abstract] [Full Text] [PDF]

				D. F. Jarrard, S. Sarkar, Y. Shi, T. R. Yeager, G. Magrane, H. Kinoshita, N. Nassif, L. Meisner, M. A. Newton, F. M. Waldman, et al. p16/pRb Pathway Alterations Are Required for Bypassing Senescence in Human Prostate Epithelial Cells Cancer Res., June 1, 1999; 59(12): 2957 - 2964. [Abstract] [Full Text] [PDF]

				S. L. Huhn, G. Mohapatra, A. Bollen, K. Lamborn, M. D. Prados, and B. G. Feuerstein Chromosomal Abnormalities in Glioblastoma Multiforme by Comparative Genomic Hybridization: Correlation with Radiation Treatment Outcome Clin. Cancer Res., June 1, 1999; 5(6): 1435 - 1443. [Abstract] [Full Text] [PDF]

				C. T. Lee, P. Capodieci, I. Osman, M. Fazzari, J. Ferrara, H. I. Scher, and C. Cordon-Cardo Overexpression of the Cyclin-dependent Kinase Inhibitor p16 Is Associated with Tumor Recurrence in Human Prostate Cancer Clin. Cancer Res., May 1, 1999; 5(5): 977 - 983. [Abstract] [Full Text] [PDF]

				M. Nozaki, M. Tada, H. Kobayashi, C.-L. Zhang, Y. Sawamura, H. Abe, N. Ishii, and E. G. Van Meir Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression Neuro-oncol, April 1, 1999; 1(2): 124 - 137. [Abstract] [PDF]

				J. R. Hill, N. Kuriyama, H. Kuriyama, and M. A. Israel Molecular Genetics of Brain Tumors Arch Neurol, April 1, 1999; 56(4): 439 - 441. [Abstract] [Full Text] [PDF]

				S. Mizumatsu, T. Tamiya, Y. Ono, T. Abe, K. Matsumoto, T. Furuta, and T. Ohmoto Expression of Cell Cycle Regulator p27Kip1 Is Correlated with Survival of Patients with Astrocytoma Clin. Cancer Res., March 1, 1999; 5(3): 551 - 557. [Abstract] [Full Text] [PDF]

				P. Kleihues and H. Ohgaki Primary and secondary glioblastomas: From concept to clinical diagnosis Neuro-oncol, January 1, 1999; 1(1): 44 - 51. [Abstract] [PDF]

				H.-X. An, M. W. Beckmann, G. Reifenberger, H. G. Bender, and D. Niederacher Gene Amplification and Overexpression of CDK4 in Sporadic Breast Carcinomas Is Associated with High Tumor Cell Proliferation Am. J. Pathol., January 1, 1999; 154(1): 113 - 118. [Abstract] [Full Text] [PDF]

				G. P. Nielsen, K. L. Burns, A. E. Rosenberg, and D. N. Louis CDKN2A Gene Deletions and Loss of p16 Expression Occur in Osteosarcomas That Lack RB Alterations Am. J. Pathol., July 1, 1998; 153(1): 159 - 163. [Abstract] [Full Text] [PDF]

				R. G. Weber, J. Bostrom, M. Wolter, M. Baudis, V. P. Collins, G. Reifenberger, and P. Lichter Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: Toward a genetic model of meningioma progression PNAS, December 23, 1997; 94(26): 14719 - 14724. [Abstract] [Full Text] [PDF]

				F. B. Furnari, H. Lin, H.-J. S. Huang, and W. K. Cavenee Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain PNAS, November 11, 1997; 94(23): 12479 - 12484. [Abstract] [Full Text] [PDF]

				J. Gray-Bablin, J. Zalvide, M. P. Fox, C. J. Knickerbocker, J. A. DeCaprio, and K. Keyomarsi Cyclin E, a redundant cyclin in breast cancer PNAS, December 24, 1996; 93(26): 15215 - 15220. [Abstract] [Full Text] [PDF]